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CHAPTER SIXTEEN 
Division of Medical 
Oncology 
WILLIAM E. DELANEY, M.D. 
"While there are several chronic diseases 
more destructive to life than cancer) 
none is more [eared.J) -CHARLES H. MAYO (1865-1939) 
ALTHOUGH medical oncology was first officially recognized as a medical subspecialty by the American Board of 
Internal Medicine in 1972, a formal Division of 
Medical Oncology in the Department of Medicine 
at Jefferson had been established since 1961. The 
first Director (1961-1970) was Arthur Weiss, M.D. 
(Figure T6-1), and the second (1970-1980) was 
Chester Southam, M.D. (Figure J6-2). Acting 
Directors were William E. Delaney, M.D. 
(Jefferson, 1953; 1980-1981) and J. Frederick 
Laucius, M.D. (Jefferson, 1967; 1981-19R4). The 
third Director is Michael J. Mastrangelo, M.D., 
appointed in 1984. 
The major activities of the Division since its 
inception have been patient care, teaching, 
research, and the training of medical oncology 
Fellows. Among the latter, the first Fellows were 
Laird Jackson, M.D., who was the first National 
Institutes of Health Postdoctoral FelJow (1961-
1962), and Harvey Brodovsky, M.D. (1961-1963). 
Several additional Fellows have served in the 
Division since that time, most notably Carla 
Goepp, M.D. (hgure 16-3), (1965-1967), who 
became Associate Dean of Student Affairs and 
Director of the Office of Student Counseling and 
Career Planning, and Michael J. Mastrangelo, 
M.D. (1968-1970). Significant accomplishments in 
cancer care, research, and teaching at Jefferson 
occurred in the years before the establishment of 
the Division. 
The Tumor Clinic and Elizabeth 
Storck I(raemer Foundation 
The Tumor Clinic was informally begun in 1928 
and has continued since that date as the major 
institutional follow-up mechanism for cancer 
patients. Formal establishment began in the fall of 
1929 when, through the auspices of William H. 
Kraemer, M.D. (Figure 16-4, Jefferson, 1906), 
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Associate Professor of Surgery, a grant received 
from Mr. Pierre S. DuPont, consisting initially of 
$35,000 plus $10,000 annually for five years, was 
augmented by an initial grant of $15,000 for one 
year from Mr. Lanunot DuPont. Through an 
additional 30 years (]934-1964-), Pierre DuPont 
provided the sole support of Jefferson's Tmuor 
Clinic through annual grants from the Longwood 
foundation to the Elizabeth Storck Kraemer 
Foundation. I 
All of the Department Chairmen have served as 
Attending Physicians or Surgeons in the Tmnor 
Clinic. Outstanding contributors to the activity of 
the Tumor Clinic over the years have been Drs. 
James M. Surver (Assistant Professor of Surgery), 
Harry]. Knowles (Assistant Professor of Surgery), 
and Gerald J. Marks (Professor of Surgery), who 
directed the day-to-day activities of the staff. 
The Tumor Registry began as an offshoot of the 
Tmnor Clinic in June, 1959. From that time 
through December 1983, as many as 28,593 patients 
have been accessioned, and 19,139 patients are 
known to have died. By June 1984-, as many as 
9,973 patients were under active follow-up, a rate 
of 92.3 percent. This Registry is the resource for 
all professionals interested in follow-up data over 
the years for Jefferson's oncology activities. Its 
overall direction is through the Cancer Committee 
of the Hospital. 
The other major activity of the Elizabeth Storck 
Kraemer Foundation was to provide an 
investigative arm for the development of new 
cancer treatment drugs that had been isolated or 
synthesized by chemists of the DuPont Company. 
Dr. Kraemer died in March, 1962, and on 
December 31, 1964-, the Foundation was dissolved. 
For nearly 35 years it had actively supported not 
only the Tmnor Clinic and weekly Tmnor Clinic 
conferences but also chemical research at the 
DuPont experimental station in Wilmington, 
FIG. ]6-1. Arthur Weiss, M.D.; First Director, Division of FIG. 16-2. Chester Southam, M.D.; Director, Division of 
Oncology (1961-1970). Oncology (1970- 1980). 
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Delaware, ,md biological research conducted 
by the Department of Pathology under the 
supervision of Dr. Peter A. Herbut. Dr. Herbut 
was Director of the Biological Division of the 
Fow1dation, incorporated from September, 194-6, 
to December 31, 1964-, on a stipend of $200 a 
month payable by the Tumor Clinic. Dr Kraemer 
was Director of Research from 1929 until his 
death. The funding after 1964- came through the 
Hospital budget. 
The first publication from the Foundation 
appeared in 1931 and was a preliminary report on 
colloidal lead phosphate with manganese as an 
anticarcinogenic agent. 2 In subsequent years the 
Foundation was responsible for 22 publications in 
experimental cancer by Dr. Herbut, 14- of which 
were coauthored with Dr. Kraemer. In a 1955 
article,3 Herbut and Kraemer stated that the 
Walker Rat Mammary Carcinoma 256 had been 
carried in their laboratory since 1936. Dr. 
Kraemer's cancer research was recognized formally 
by his Jefferson alma mater in the award of an 
Honorary Degree of Doctor of Science at 
graduation on June 16, 1961. 
William H. Kraemer (born 1879) came to the 
United States as a boy from Germany. The family 
settled in West Virginia where he learned frugality 
and a proper set of values. He was trained as a 
pharmacist, and his application to Jefferson was 
accepted on the basis of his pharmacy credits. He 
worked at pharmacies during medical school and 
graduated in 1906. While working as a physician 
with the DuPont Company, he began to 
experiment on cancer in his garage using rats he 
caught there. 
In 1926 Dr. Kraemer attracted the attention of 
Pierre S. DuPont, who requested his treatment for 
a leg ulcer that DuPont attributed to a kick by 
John J. Raskob intended to keep him awake 
during a General Motors Corporation board 
meeting. Dr. Kraemer had x-rays talcen of Du 
Pont's teeth out of desperation because he had 
FIG. 16-3. Carla Goepp, M.D. FIG. [6-4. William H. Kraemer, M.D. 
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found nothing systemically to account for the 
poor healing. The film revealed two abscessed 
wisdom teeth on each side, which Kraemer 
believed to have contributed to DuPont's 
somnolence. He immediately brought his patient 
to Jefferson, and taking a hospital room next to 
DuPont for himself, began to take care of all his 
health needs, including extraction of the teeth. 
Although the mandible was fractured in the 
extraction of the teeth, rendering DuPont 
speechless for a time, DuPont was grateful because 
his somnolence completely disappeared. While 
recuperating, DuPont communicated with Dr. 
Kraemer by written notes. In one of them he 
asked: "What is this I hear about your 
experimenting with cancer in the garage?" Dr. 
Kraemer told him about it and suggested that 
DuPont Company's vast chemical expertise be 
used to develop cancer chemotherapy. 
In addition to personal physician, Dr. Kraemer 
became a friend and confidant. He played golf 
with DuPont, went on trips with him, and with 
Mrs. Kraemer moved to the DuPont area. Mr 
DuPont put him on a lifetime retainer of $6,000 
per year and gave Mrs. Kraemer $5,000 per year 
for life. He also set up the Elizabeth Storck 
Kraemer Memorial Foundation in honor of Dr. 
Kraemer's second wife, who died of cancer. 
In the early years, the biological aspect was 
carried out in New York's Memorial Hospital for 
Cancer, through Dr. James Ewing and later at 
New York University by Dr. Robert Chambers. In 
the mid-1940S, following Dr. Chamber's death, 
biological studies were centered at Jefferson. The 
chemical division of the Elizabeth Storck Kraemer 
Memorial Foundation was headquartered in the 
experimental station in Wilmington, Delaware. 
Toward the end, the annual budget of the 
Foundation should be funded for ten years after 
his death or until Dr. Kraemer died, whichever 
was longer. Pierre DuPont died in 1954. William 
H. Kraemer died March 20, 1962, and the 
Foundation was dissolved December 31, 1964. The 
Directors in 1964 are listed in Volume 2 of the 
Herbut Papers in the Scott Library's Special 
Collections. The Foundation was headquartered in 
room 2095, DuPont Building, Wilmington, 
Delaware. By December 3, 1959, the Foundation 
had completed its thirty-first year of activity, and 
during that time 4,000 chemicals had been 
screened for antitumor activity and 1,000 cancer 
patients had received chemotherapy. Mter the 1964 
termination of the research support, the Trustees 
of the Foundation granted $24,650 to Jefferson 
Medical College for research at Dr. Herbut's 
discretion. As an outgrowth of the research 
activities that had been supported by the Kraemer 
Foundation, a National Institutes of Health grant 
award to Dr. Herbut was renewed for three years 
in 1965. 
The Interdepartmental Endocrine 
and Cancer Research Group 
The relationship between Drs. Abrahanl Cantarow 
(Biochemistry), Karl E. Paschkis (Medicine) 
(Figure 16-5), and Abraham E. Rakoff (Obstetrics 
and Gynecology) led to their formation of an 
informal endocrine and cancer research group in 
1940. In 1945, at the close of World War II, they 
began to contribute significantly to the literature, 
and by 1959 they had realized more than 300 
publications. The Board of Trustees in 1948 
formally organized the Endocrine and Cancer 
Research Group with Dr. Paschkis as the first and 
only Director. He was the unique catalyst who 
was involved in all activities of the group. It 
received partial funding by the American Cancer 
Society on the recommendation of the Committee 
on Growth of the National Research Council and 
by the National Cancer Institute. 
In the field of steroid hormone metabolism they 
originated the concept of the biliary excretion and 
enterohepatic circulation of estrogens and 
androgens.4 They first showed that androgens 
accelerated the development of malignant 
hepatomas when the carcinogen 2-acetyl-amino-
fluorine (AAF) was fed to rats and that thiouracil 
given with this chemical protected the liver 
exposed to testosterone; in addition, they first 
demonstrated the enhancement of the carcinogenic 
action of progesterone on the breasts of rats 
treated with AAF.5 Their work on pyrimidine 
metabolism as related to normal growth of 
malignant tumors led to the synthesis by Charles 
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Heidelberg, Ph.D., at the University of Wisconsin, 
of 5-fluorouracil, a drug widely used in many 
cancer chemotherapy programs. 6 Their research 
further indicated that in the presence of 
regenerating liver, not only tumor growth but also 
a large variety of nonmalignant growth proce:scs 
were stimulated; similar effects could be obtamed 
by injection of certain liver fractions.? Another 
basic investigation was the transmission of tumor 
by subcellular units. Thus, injection of isolated 
tumor chromatin induced tumor growth m 
recipient animals. The effect was noted to be 
specific in that chromatin from malignant 
lymphoma cells induced malignant lymp~oma 
after subcutaneous injection and chromatm 
from hepatoma cells induced hepatomas after 
1Ointrahepatic injection.8-
Dr. Paschkis faced his own terminal illness from 
bronchogenic carcinoma with composed heroism. 
With his death of January 27, 1961, at age 65, the 
Endocrine and Cancer Research Group ceased to 
function as a unit and was dissolved. 
Cooperative Cancer Therapy 
Groups 
Among the earliest investigators cooperating with 
other institutions in the evaluation of new drugs 
tor the management of cancer, Arthur Weiss, 
M.D., Assistant Professor of Medicine, was the 
leader at Jefferson since 1958, when he established 
the Jefferson branch of the Clinical Drug 
Evaluation Program of the Cancer Chemotherapy 
National Service Center, a subsidiary of the 
National Cancer Institute. In 1960, Dr. Weiss also 
led Jefferson into the Central Oncology Group as 
a cochairman of that body. In addition, in 1960, 
Farid Haurani, M.D., became the representative at 
Jefferson of the Cancer and Acute Leu.kemia 
Group B in an association that lasted through 
1981. Eastern Cooperative Oncology Group 
participation has been continuous since 1968 at 
Jefferson under the direction of Harvey 
Brodovsky, M.D. He has been a coauthor of 17 
papers published on EC?G trials and was a gr~nt 
recipient of ECOG fundll1g for many years until 
1981. 
A significant contribution to the use of 
adriamycin in chemotherapy occurred when the 
Cooperative Group, wid1 Arthur WeISS, ~.D., as 
d1e senior author and R. William MantheI, Ph.D., 
Professor of Pharmacology, as coauthor, reported 
the decrease in cardiac toxicity of low-dose 
infusions at frequent intervals as compared to the 
significant cardiac toxicity of high-dose bolus 
therapy with this drug." This modified the 
approach to the use of this excellent . 
chemotherapeutic agent and has extended Its 
useful application in aU fields of cancer 
chemotherapy. 
Applied Research and Clinical 
Oncology 
Shortly after exfoliative cytology was .develop~d in 
the early 194-0S by Dr. George PapanIColaou, ItsFIG. [6-5. Karl Paschkis, M.D. 
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application to the detection and eradication of 
gynecologic tumors was led by such men at 
Jefferson as Lewis C. Scheffey (Jefferson, 1920), 
Professor of Gynecology, and Abraham E. Rakoff 
(Jefferson, 1937), Professor of Gynecologic and 
Obstetrical Endocrinology. 
The bronchoscopic diagnosis in lung cancer by 
cytology studies of aspirated secretions won for 
Louis H. Clerf (Jefferson, 1912), Chairman of the 
Department of Otolaryngology, and Peter A. 
Herbut, Chairman of the Department of 
Pathology, the Gold Medal of the American 
Medical Association in 195I. 
Early research into naturally occurring 
stimulators and inhibitors of granulocytic and 
lymphocytic proliferation in human leukemia was 
the special interest of Franklin Miller, M.D., 
Assistant Professor of Medicine, who was one of 
the early associate members of the Cardeza 
Foundation for Hematologic Research. 
In the management of human breast cancer in 
the 1950S, when endocrine manipulation of the 
tumor was the major therapeutic modality, Ralph 
A. Carabasi (J efferson, 194-6) was a pioneer. Early 
immunologic studies in cancer were conducted by 
Irwin L. Stoloff (Jefferson, 1951), in addition to 
those performed by Chester Southam, M.D. 
Lymphangiography was originally described as a 
unilateral procedure for the analysis of lymph flow 
in 1955. In 1960, Dr. Phillip Hodes, Professor and 
Chairman of Radiology, and Dr. Simon Kramer, 
Head of Radiation Therapy, realized that this 
technique might be adaptable to the evaluation of 
lymph node involvement by cancer. They 
encouraged Sidney Wallace, M.D., Assistant 
Professor of Radiology, and Laird Jackson, M.D., 
who was then a medical resident, to develop the 
procedure. Drs. Wallace and Jackson performed 
the first bilateral simultaneous injection of 
intralymphatic contrast materials in humans in 
1960. This was a tedious procedure in the 
beginning, requiring prolonged hand-delivered 
injections by two people, until Dr. Jackson 
invented a motor-driven pump that became 
universally used for lymphangiography. By 1985 the 
information gained by lymphangiography was 
largely replaced by noninvasive methods. 
Laird G. Jackson, M.D., Professor of Pediatrics, 
Director of the Division of Genetics, Professor of 
Medicine and Professor of Obstetrics and 
Gynecology, performed all of his early work in 
chromosomes and on the genetics of cancer while 
assigned to the Division of Medical Oncology of 
the Department of Medicine. This began in 1961 
when he was a medical oncology Fellow and 
investigated chromosomes in leukemia. He 
expanded this work after he took the Bar Harbor 
course in medical genetics given by Victor 
McCusick, M.D., in 1962. 
With the return of Michael J. Mastrangelo, 
M.D. (Figure 16-6) to Jefferson in 1984- to renew 
an association he had begun as a medical intern in 
1964-, Jefferson entered a new era of research and 
therapy of malignant melanomas. Dr. 
Mastrangelo's interest has been in the 
immunologic aspects of cancers in general and of 
malignant melanoma in particular since he took 
postdoctoral training in the laboratory of 
Richmond T. Prehn, M.D., in the Institute for 
Cancer Research of Philadelphia (1971-1972). 
Mastrangelo was an early member of the 
Malignant Melanoma Clinical Cooperative Group 
(1973-1977) and a member of the Committee on 
Tumor Immunotherapy of the Division of Cancer 
Biology and Diagnosis of the National Cancer 
FIG. 16-6. Michael J. Mastrangelo, M.D.; Director, 
Division of Oncology (1984-). 
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Institute (1975-1979). Since 1980 he has been a 
member of the Experimental Therapeutic Study 
Section of the National Institutes of Health, 
serving from 1982 to 1984 as its Chairman. He 
continues an active program in immunologic 
aspects of cancer and of malignant melanoma in 
particular. 
Medical science is still at the frontier in 
understanding the complex mechanisms that lead 
to cancer, its better palliation, and the ultimate 
goal of total prevention and cure. The progress 
thus far engendered by interdepartmental 
cooperation has been significant, but more intense 
focus on the possible role of viruses not yet 
isolated, genetic investigation, and study of 
neoplasms at the molecular level will increase 
Jefferson's stature in this field. 
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